Skip to main content
Symptom
dx.
Menu
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Symptom
dx.
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Get Started
Menu
Clinical Reference
Approaches
I have a symptom
Management
I know the diagnosis
Orthopedic Injuries
Fractures & dislocations
Calculators
Clinical calculators
Practical Skills
ECG
Interpretation guide
POCUS
Bedside ultrasound
Procedures
Step-by-step guides
Resuscitation
ACLS / PALS / NRP
Learn
Blog
Articles & updates
Deep Dive
In-depth clinical reviews
About
Our mission
Loading...
African Sleeping Sickness
Cardiovascular Presentations
Abdominal aortic aneurysm
Acute coronary syndrome (NSTEMI)
Acute coronary syndrome (STEMI)
Acute decompensated heart failure
Acute limb ischemia
Acute mesenteric ischemia
Aortic dissection
Aortic stenosis
Atrial fibrillation and flutter
Bradyarrhythmia and heart block
Cardiac arrest
Deep vein thrombosis
Myocarditis
Pericarditis
Pulmonary embolism
Stable angina
Superficial thrombophlebitis
Superior vena cava syndrome
Supraventricular tachycardia
Syncope (cardiogenic)
Unstable angina
Ventricular tachycardia
Respiratory Presentations
Acute bronchitis
Acute respiratory failure
Aspiration pneumonia
Asthma exacerbation
Bronchiolitis
Community-acquired pneumonia
COVID-19 pneumonia
COPD exacerbation
Croup
Croup (laryngotracheobronchitis)
Epiglottitis
Hemothorax
Hospital-acquired pneumonia
Pleural effusion
Pneumothorax (traumatic)
Pulmonary contusion
Spontaneous pneumothorax
Neurological Presentations
Bell's palsy
Benign paroxysmal positional vertigo
Brain abscess
Cauda equina syndrome
Cervical radiculopathy
Concussion (mild traumatic brain injury)
Encephalitis
Guillain-Barré syndrome
Hemorrhagic stroke (intracerebral)
Ischemic stroke
Lumbar radiculopathy
Malignant spinal cord compression
Migraine
Peripheral neuropathy (acute)
Retropharyngeal abscess
Schizophrenia (acute exacerbation)
Seizure (breakthrough:known epilepsy)
Seizure (first-time)
Spinal cord injury
Status epilepticus
Subarachnoid hemorrhage
Tension headache
Transient ischemic attack
Traumatic brain injury (moderate-severe)
Vestibular neuritis
Viral meningitis
Gastrointestinal Presentations
Acute appendicitis
Acute cholecystitis
Acute diverticulitis
Acute pancreatitis
Anal fissure
Choledocholithiasis and cholangitis
Clostridioides difficile colitis
Gastritis
Gastroenteritis (viral and bacterial)
Gastroesophageal reflux disease
Incarcerated or strangulated hernia
Inflammatory bowel disease flare
Large bowel obstruction
Lower GI hemorrhage
Peptic ulcer disease
Perforated viscus
Small bowel obstruction
Upper GI hemorrhage
Genitourinary and Reproductive Presentations
Acute prostatitis
Acute urinary retention
Ectopic pregnancy
Epididymitis
Orchitis
Ovarian torsion
Paraphimosis
Pelvic inflammatory disease
Priapism
Pyelonephritis
Renal laceration
Ruptured ovarian cyst
Testicular torsion
Tubo-ovarian abscess
Urinary tract infection (uncomplicated)
Urolithiasis (renal colic)
Vaginal bleeding (non-pregnant)
Infectious Disease Presentations
Acute sinusitis
Acute tonsillitis
Acute upper respiratory infection
Animal bite
Bacterial meningitis
Cellulitis
Conjunctivitis (bacterial)
Dental abscess
Endocarditis
Febrile neutropenia
Fournier gangrene
Hand-foot-mouth disease
Hepatitis (acute)
Herpes zoster
HIV-related illness
Human bite
Impetigo
Infected diabetic foot ulcer
Infectious mononucleosis
Influenza
Necrotizing fasciitis
Osteomyelitis
Otitis externa
Parasitic infection
Periorbital cellulitis
Peritonsillar abscess
Scabies
Sepsis
Septic arthritis
Spontaneous bacterial peritonitis
Tick-borne illness (Lyme disease)
Tinea infection
Tuberculosis
Viral exanthem
Wound infection
Trauma Presentations
Achilles tendon rupture
ACL and mceniscus tear
Ankle fracture
Ankle sprain
Burn
Calcaneus fracture
Cervical spine fracture
Clavicle fracture
Dental avulsion
Distal radius fracture
Drowning
Elbow fracture and dislocation
Electrical injury
Facial bone fracture
Facial laceration
Femur fracture
Fingertip amputation
Forearm fracture (radius and ulna)
Frostbite
Hand:finger laceration
Heat exhaustion
Heat stroke
Hip fracture
Humeral shaft fracture
Knee dislocation
Knee sprain
Lightning injury
Mandible fracture
Metacarpal fracture
Metatarsal fracture
Muscle strain
Nasal fracture
Non-accidental trauma
Orbital fracture
Patella fracture
Phalanx fracture (finger)
Proximal humerus fracture
Pulmonary contusion
Rib fracture
Rotator cuff tear (acute traumatic)
Scalp laceration
Scaphoid fracture
Shoulder dislocation
Skull fracture
Splenic laceration
Sternal fracture
Supracondylar pediatric fracture
Tendon laceration (hand:wrist)
Thoracic and lumbar spine fracture
Tibia:fibula fracture
Tibial plateau fracture
Toe fracture
Traumatic epistaxis
Traumatic hyphema
Toxicologic Presentations
Acetaminophen toxicity
Alcohol intoxication
Alcohol withdrawal
Anticholinergic toxicity
Anticoagulant overdose
Benzodiazepine overdose
Benzodiazepine:sedative overdose
Beta-blocker and calcium channel blocker toxicity
Carbon monoxide poisoning
Caustic ingestion
Digoxin toxicity
Drug eruption
Foreign body ingestion
Opioid intoxication
Opioid overdose
Opioid withdrawal
Organophosphate
Salicylate toxicity
Serotonin syndrome
Stimulant intoxication (cocaine, methamphetamine)
Tricyclic antidepressant overdose
Psychiatric Presentations
Acute anxiety
Acute psychosis
Agitation:behavioral emergency
Bipolar disorder
Conversion disorder
Major depressive episode
Neuroleptic malignant syndrome
Suicidal ideation and attempt
Musculoskeletal and Rheumatologic Presentations
Acute low back pain (mechanical)
Bursitis
Cervical radiculopathy
Costochondritis
Gout (acute)
Lumbar radiculopathy
Pseudogout
Tendinitis
Dermatology Presentations
Acute eczema (Eczema acute flare)
Allergic contact dermatitis
Erythema multiforme
Henoch-Schönlein purpura
Pressure injury
Psoriasis (acute flare)
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Urticaria (acute)
Environmental and Exposure Presentations
Envenomation (snake, spider, insect)
High-altitude illness
Hypothermia
Hematologic and Oncologic Presentations
Acute chest syndrome
Coagulopathy
Hyperviscosity syndrome
Sickle cell crisis (vaso-occlusive)
Symptomatic anemia
Thrombocytopenia (severe)
Tumor lysis syndrome
Pediatric-Specific Presentations
Bronchiolitis
Croup
Emergency delivery
Febrile seizure
Kawasaki disease
Neonatal jaundice
Neonatal sepsis
Nursemaid's elbow
Pediatric fever 0 to 28 days
Pediatric fever 29 to 60 days
Pediatric fever 61 to 90 days
Pyloric stenosis
Slipped capital femoral epiphysis
Intussusception
Endocrine and Metabolic Presentations
Adrenal crisis
Diabetic ketoacidosis
Hypercalcemia
Hyperosmolar hyperglycemic state
Hypertensive emergency
Hypertensive urgency
Hypoglycemia
Myasthenia gravis crisis
Myxedema coma
Severe hyperkalemia
Severe hyponatremia
Thyroid storm
ENT and Maxillofacial Presentations
Acute laryngitis
Acute otitis media
Acute pharyngitis
Cerumen impaction
Epistaxis (anterior)
Nasal foreign body
Otitis externa
Tympanic membrane perforation
Ophthalmologic Presentations
Acute angle-closure glaucoma
Central retinal artery occlusion
Chemical eye injury
Corneal abrasion
Corneal ulcer
Globe rupture
Ocular foreign body
Orbital cellulitis
Retinal detachment
Obstetric Presentations
Hyperemesis gravidarum
Painful vaginal bleeding in pregnancy
Placenta previa
Placental abruption
Preeclampsia:eclampsia
Preterm labor
Threatened:inevitable:incomplete abortion
Systemic and Miscellaneous Presentations
Anaphylaxis
Angioedema
Cannabis-induced hyperemesis
African Sleeping Sickness
POCUS
Procedures
Calculators
Resuscitation
ECG Guide
Back
Clinical Assessment Checklist
Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Recognize the life-threatening course
▶
Rhodesiense pattern (acute, days to weeks)
▶
Severe sepsis-like presentation
Death possible before neurological signs appear
Gambiense pattern (chronic, months to years)
▶
Insidious progression to meningoencephalitis
Mean disease duration about 3 years untreated
Fatal if untreated regardless of subspecies
▶
Neglected tropical disease, WHO-notifiable
Early definitive treatment is curative
Airway, breathing, circulation
▶
Airway protection in advanced second-stage coma
▶
Depressed consciousness
Seizure-related compromise
Circulatory threats in rhodesiense
▶
Myocarditis with cardiogenic shock
Pericardial effusion with tamponade physiology
If hemodynamic instability, treat as cardiac involvement until excluded
▶
IV access and continuous monitoring
Bedside echocardiography
Concurrent tropical co-infection
▶
Empiric malaria evaluation in every febrile returned traveler
▶
Thick and thin films for Plasmodium
Treat malaria if confirmed
Fever not responding to antimalarials is a key trypanosomiasis clue
▶
No typical malaria periodicity
Persistent recurrent fever despite therapy
Key decision points
Diagnosis confirmation before specific therapy
▶
Parasitological confirmation is the standard
▶
Blood film, lymph node aspirate, or chancre aspirate
CSF for staging
Empiric trypanocidal therapy only when confirmation impossible and risk high
▶
Infectious disease guidance required
Document rationale
Staging determines drug choice
▶
Stage 1 haemolymphatic (no CNS involvement)
▶
CSF WBC at or below 5/uL
No trypomastigotes in CSF
Stage 2 meningoencephalitic
▶
CSF WBC above 5/uL or trypanosomes in CSF
Severe stage 2 at CSF WBC at or above 100/uL
Team activation and consults
Escalation triggers
▶
Infectious disease and tropical medicine consultation
▶
Essential in non-endemic settings
Drug access coordination
Public health and CDC notification
▶
CDC Parasitic Diseases hotline for drug release in the US
WHO strategic emergency drug depots
ICU referral for rhodesiense instability
▶
Multiorgan failure
Refractory shock
History
Travel and exposure
Travel history is paramount
▶
Sub-Saharan Africa, rural or forested areas
▶
Tsetse fly (Glossina) habitat near rivers and woodland
Specific country, duration, urban versus rural
Region predicts subspecies
▶
Gambiense in West and Central Africa
Rhodesiense in East and Southern Africa
Democratic Republic of the Congo accounts for over 80% of gambiense cases
▶
Remote travel still relevant given long incubation
Safari, aid work, research, fieldwork
High-exposure activities
▶
Farming and water collection
▶
Riverine and forest edge work
Daytime tsetse biting
Hunting, fishing, wood gathering
▶
Bushland entry
Lack of protective clothing
Symptom timeline
Incubation and tempo
▶
Gambiense incubation months to years
▶
Insidious chronic course
Often misdiagnosed as malaria
Rhodesiense incubation days to 3 weeks
▶
Rapid progression
Fatal within days to weeks if untreated
Stage 1 symptoms
▶
Intermittent fever (irregular pattern)
▶
No antimalarial response
Night sweats
Headache and malaise
▶
Persistent and worsening
Arthralgias and fatigue
Pruritus and weight loss
▶
Generalized itching
Progressive cachexia
Stage 2 symptoms
▶
Sleep-wake cycle disruption
▶
Daytime somnolence
Nocturnal insomnia
Behavioral and psychiatric change
▶
Confusion and logorrhoea
Anxiety and irritability
Motor and movement symptoms
▶
Tremor and ataxia
Speech impairment and seizures
Key clues and negatives
Discriminating features
▶
Painful skin lesion at bite site (trypanosomal chancre)
▶
More common in rhodesiense
Up to 88% in travelers
Recurrent fever despite antimalarials
▶
Key pointer away from malaria
No classic malarial periodicity
Past medical and exposure history
▶
Prior HAT episode or treatment
▶
Relapse risk
Cross-resistance nifurtimox and fexinidazole
Comorbidity relevant to therapy
▶
HIV status and co-infection
Cardiac, renal, hepatic, psychiatric history
Physical Exam
Vitals and general
Stability snapshot
▶
Temperature
▶
Intermittent irregular fever
Hypothermia as severe sepsis marker
Heart rate and blood pressure
▶
Tachycardia with cardiac involvement
Hypotension in rhodesiense
Mental status
▶
Somnolence
Confusion and behavioral change
Classic findings
Lymphatic and skin signs
▶
Winterbottom's sign
▶
Painless soft posterior cervical lymphadenopathy
Classic for gambiense HAT
Trypanosomal chancre
▶
Painful erythematous lesion 2 to 5 cm at bite site
No necrosis, larger than typical eschar
Trypanosomal rash
▶
Circinate or serpentine outline
Transient and migratory
Visceral findings
▶
Hepatosplenomegaly
▶
Common in systemic disease
Mimics other tropical infections
Facial and peripheral edema
▶
Soft tissue swelling
Periorbital involvement
Neurological and cardiac exam
Neurological assessment
▶
Movement abnormalities
▶
Tremor and ataxia
Abnormal gait and abnormal movements
Motor and speech findings
▶
Motor weakness
Speech impairment
Kerandel's sign
▶
Delayed hyperaesthesia at bone crests
Supports CNS involvement
Cardiac assessment
▶
Myocarditis signs
▶
Gallop and tachyarrhythmia
Heart failure features
Pericardial involvement
▶
Muffled heart sounds
Pericardial effusion signs
PITFALLS
Diagnostic traps
▶
Misattributing fever to malaria alone
▶
Dual infection possible
Reassess if no antimalarial response
Chancre mistaken for arthropod bite or rickettsial eschar
▶
Larger and non-necrotic
Aspirate can detect trypanosomes early
Travelers present atypically
▶
Winterbottom's sign and somnolence less common
Diarrhea and jaundice may suggest GI illness
Differential Diagnosis
Life-threatening and infectious mimics
Must-not-miss infections
▶
Malaria
▶
Most common misdiagnosis
ICD-10 B54
Bacterial meningitis or viral encephalitis
▶
Altered mental status and CSF pleocytosis
ICD-10 A87.9 for viral encephalitis
Severe sepsis from other source
▶
Overlaps rhodesiense presentation
ICD-10 A41.9
Chronic febrile mimics
▶
HIV infection
▶
Lymphadenopathy, weight loss, neuropsychiatric features
ICD-10 B20
Tuberculosis
▶
Chronic fever, weight loss, lymphadenopathy
ICD-10 A15.9
Typhoid fever and brucellosis
▶
Prolonged fever, hepatosplenomegaly, arthralgias
Undulant fever pattern in brucellosis
Parasitic and neoplastic differentials
Other tropical parasites
▶
Visceral leishmaniasis
▶
Hepatosplenomegaly, fever, pancytopenia
ICD-10 B55.0
Toxoplasmosis
▶
CNS involvement in immunocompromised
ICD-10 B58.2 for meningoencephalitis
Neoplastic and other
▶
Lymphoma
▶
Generalized lymphadenopathy and B symptoms
ICD-10 C85.9
Human African trypanosomiasis itself
▶
Gambiense ICD-10 B56.0
Rhodesiense ICD-10 B56.1
Differentiating clues
Distinguishing features
▶
Geography and exposure
▶
Tsetse fly contact narrows differential
Subspecies by region
Sleep disturbance with lymphadenopathy
▶
Suggests gambiense second stage
Winterbottom's sign supportive
Fever refractory to antimalarials
▶
Points toward HAT
Prompts parasitological search
Laboratory Tests
Parasitological confirmation
Direct parasite detection
▶
Giemsa-stained thick and thin blood films
▶
Gold standard for rhodesiense (high parasitemia)
Repeat exams and concentration for gambiense
Buffy coat preparation
▶
Concentrates trypanosomes
About 50% sensitivity for gambiense
Mini anion exchange centrifugation technique (mAECT)
▶
About 80% sensitivity for gambiense
Concentration method for low parasitemia
Aspirate microscopy
▶
Lymph node aspirate
▶
When palpable cervical nodes present
Direct trypanosome visualization
Chancre aspirate
▶
Detects trypanosomes within days of rhodesiense infection
Early diagnostic window
Serology and molecular
Serological screening (gambiense only)
▶
CATT (Card Agglutination Test for Trypanosomiasis)
▶
Titer at or above 1:16 considered positive
Field screening tool
Lateral flow rapid diagnostic tests
▶
HAT Sero K-SeT sensitivity about 100%
Specificity about 94%
Confirmatory reference assays
▶
Trypanolysis test specific for gambiense contact
Indirect ELISA gambiense specificity about 99%
Molecular testing
▶
PCR via CDC or reference labs
▶
Sensitivity about 99%
Specificity about 98%
Limited field availability
▶
Confirmatory and research role
Not first-line in resource-limited settings
Supportive labs
Hematology and chemistry
▶
Complete blood count
▶
Anemia and thrombocytopenia
Leukocytosis
Comprehensive metabolic panel
▶
Baseline renal function before suramin (nephrotoxic)
Hepatic function for drug metabolism
Pre-treatment safety labs
▶
Baseline ECG and electrolytes before fexinidazole
▶
QT prolongation risk
Correct potassium and magnesium
Glucose monitoring
▶
Pentamidine-induced hypoglycemia
Hyperglycemia surveillance
Diagnostic Tests
Scoring Systems
Disease staging classification
▶
Stage 1 haemolymphatic
▶
CSF WBC at or below 5/uL
No trypanosomes in CSF
Stage 2 meningoencephalitic
▶
CSF WBC above 5/uL
Or trypanosomes detected in CSF
Severe stage 2 threshold
▶
CSF WBC at or above 100/uL
Favors NECT over fexinidazole for gambiense
Lumbar puncture decision
▶
Required in children under 6 years or under 20 kg
▶
Staging mandatory for drug choice
Neurological signs present
May be deferred in adults without neuro signs when fexinidazole planned
▶
Simplified staging-free pathway
WHO 2019 to 2020 guidance
No validated ED prognostic score
▶
Staging drives management
Clinical trajectory supersedes single value
MRI
Brain MRI role
▶
Second-stage findings
▶
White matter signal change
Meningoencephalitic features
Not routinely required
▶
Staging relies on CSF examination
Adjunct when diagnosis unclear
Contraindications and limits
▶
Unstable patient
Non-compatible implants
CT
CT head role
▶
Excludes alternative pathology
▶
Mass lesion
Hemorrhage before lumbar puncture if focal deficit
Non-specific for HAT
▶
No diagnostic CT signature
Cerebral atrophy in advanced disease
Contrast considerations
▶
Renal function assessment
Allergy history
CT chest role
▶
When pericardial effusion or pulmonary edema suspected
▶
Rhodesiense cardiac involvement
Adjunct to echocardiography
Ultrasound
Echocardiography
▶
Indicated in rhodesiense HAT
▶
Myocarditis evaluation
Pericardial effusion and cardiac dysfunction
Tamponade assessment
▶
Diastolic chamber collapse
IVC plethora
Serial monitoring during illness
▶
Track effusion size
Guide pericardiocentesis
Abdominal point-of-care ultrasound
▶
Hepatosplenomegaly confirmation
▶
Organ size assessment
Free fluid screen
Lymphadenopathy characterization
▶
Cervical node assessment
Aspiration guidance
Disposition
Level of care
Admission indications
▶
All confirmed HAT cases
▶
Treatment initiation, monitoring, staging
Directly observed therapy
Fexinidazole course logistics
▶
10 days of observed dosing with food
Ideally in a health facility
NECT requirement
▶
Hospitalization for IV eflornithine infusions
Nursing-intensive regimen
ICU indications
▶
Rhodesiense instability
▶
Hemodynamic compromise
Cardiac involvement
Multiorgan failure
▶
Renal or hepatic dysfunction
Severe encephalopathy
Coordination and follow-up
Copy
Consultation and drug access
▶
Infectious disease consultation essential
▶
Non-endemic management expertise
Staging interpretation
CDC Parasitic Diseases hotline (US)
▶
Drug release coordination
Management guidance
WHO strategic drug depots
▶
Donated drug supply
International coordination
Post-treatment follow-up
▶
Gambiense after fexinidazole
▶
Assessment at 6, 12, 18, and 24 months
Any time if symptoms recur
Rhodesiense after fexinidazole
▶
End of treatment, then 1, 3, 6, and 12 months
Clinical vigilance maintained
Treatment
Initial stabilization
Resuscitation priorities
▶
IV access and hemodynamic monitoring
▶
Especially rhodesiense
Continuous cardiac monitoring
Treat concurrent malaria if present
▶
Confirm and treat per protocol
Do not delay HAT workup
Rhodesiense treated without delay
▶
Rapid progression to multiorgan failure
Early specialist involvement
First-line by stage gambiense
Fexinidazole oral (first-line, most cases)
▶
Indication
▶
Age at or above 6 years and at least 20 kg
No severe neurological signs
Dosing schedule
▶
Loading dose once daily for 4 days
Maintenance dose once daily for 6 days
Total 10-day directly observed course
Administration
▶
Must be taken with a substantial meal
Fasting compromises absorption and risks failure
Pentamidine IM for early gambiense in young children
▶
Indication
▶
Under 6 years or under 20 kg, stage 1
When fexinidazole unsuitable
Dosing
▶
4 mg/kg IM once daily for 7 days
Monitor for severe hypotension and hypoglycemia
NECT for severe second-stage gambiense
▶
Indication
▶
CSF WBC at or above 100/uL
Severe meningoencephalitic disease
Eflornithine component
▶
200 mg/kg IV every 12 hours for 7 days
Slow infusion over at least 1 to 2 hours
Nifurtimox component
▶
15 mg/kg per day PO divided every 8 hours for 10 days
Taken with food
First-line by stage rhodesiense
Fexinidazole oral (first-line)
▶
Indication
▶
Age at or above 6 years and at least 20 kg
Both stages per 2024 WHO guidance
Same 10-day schedule
▶
Loading 4 days then maintenance 6 days
Taken with food, directly observed
Suramin IV for early rhodesiense in young children
▶
Indication
▶
Under 6 years or under 20 kg, stage 1
Bridge when fexinidazole unavailable
Dosing and precautions
▶
Test dose first due to anaphylaxis risk
About 20 mg/kg IV weekly for 5 weeks
Nephrotoxic, monitor renal function and urinalysis
Melarsoprol IV for second-stage rhodesiense (last resort)
▶
Indication
▶
Under 6 years or under 20 kg
When fexinidazole cannot be given
Risk profile
▶
Reactive encephalopathy in about 7%
Treatment-related death in 3 to 8%
No longer recommended for gambiense due to toxicity
Monitoring and pearls
Fexinidazole safety monitoring
▶
Neuropsychiatric adverse effects
▶
Hallucinations, psychotic disorder, suicidal ideation
Insomnia and tremor
Cardiac and hematologic monitoring
▶
Baseline and on-treatment ECG for QT prolongation
Watch for neutropenia
Avoid concurrent QT-prolonging drugs
▶
Review medication list
Correct electrolytes
Supportive and pipeline considerations
▶
Nutritional and hydration support
▶
Cachexia in advanced disease
Vomiting from fexinidazole in about 38%
Acoziborole single oral dose (pipeline)
▶
Phase 2 and 3 efficacy in gambiense both stages
Not yet standard of care
Special Populations
Pregnancy
Pregnancy considerations
▶
Treatment urgency
▶
Untreated HAT is fatal and harms the fetus
Specialist-guided therapy
Drug safety
▶
Limited fexinidazole pregnancy data, weigh risk and benefit
Pentamidine used when benefit outweighs risk
Monitoring
▶
Fetal surveillance when viable gestation
Maternal glucose and blood pressure with pentamidine
Geriatric
Older adult features
▶
Comorbidity burden
▶
Cardiac and renal impairment affect drug choice
Suramin nephrotoxicity risk higher
Drug interaction risk
▶
Polypharmacy and QT-prolonging agents
Heightened neuropsychiatric sensitivity
Atypical presentation
▶
Confusion may dominate
Lower physiologic reserve
Pediatrics
Pediatric approach
▶
Weight and age thresholds drive therapy
▶
Fexinidazole for at least 6 years and 20 kg
Alternative agents below threshold
Stage 1 alternatives below threshold
▶
Pentamidine 4 mg/kg IM daily for 7 days for gambiense
Suramin weekly for 5 weeks for rhodesiense
Stage 2 alternatives below threshold
▶
NECT for gambiense
Melarsoprol for rhodesiense as last resort
Mandatory lumbar puncture for staging
▶
Required under 6 years or under 20 kg
Guides drug selection
Background
Epidemiology
Global burden and distribution
▶
Caused by Trypanosoma brucei subspecies
▶
Gambiense about 95% of cases, chronic
Rhodesiense about 5% of cases, acute
Geographic concentration
▶
DRC accounts for over 80% of gambiense cases
Rhodesiense in Uganda, Malawi, Tanzania, Zambia
Transmission and prevention
▶
Vector tsetse fly (Glossina) bite
No vaccine or chemoprophylaxis available
Outcome and elimination
▶
Fatal if untreated
▶
Mean gambiense duration about 3 years
Rhodesiense fatal within days to weeks
WHO elimination target
▶
Elimination as a public health problem by 2030
Declining global case counts
Pathophysiology
Disease mechanism
▶
Two-stage progression
▶
Stage 1 haemolymphatic dissemination
Stage 2 CNS invasion (meningoencephalitis)
Immune evasion
▶
Antigenic variation of variant surface glycoprotein
Evades host antibody response
CNS and sleep disruption
▶
Crossing blood-brain barrier
Circadian and sleep-wake dysregulation
Organ involvement
▶
Cardiac in rhodesiense
▶
Myocarditis and pericarditis
Heart failure before neurological signs
Systemic effects
▶
Lymphadenopathy and hepatosplenomegaly
Cachexia in advanced disease
Therapeutic Considerations
Drug access and stewardship
▶
Six drugs donated and distributed free via WHO
▶
Fexinidazole, pentamidine, suramin
Eflornithine, nifurtimox, melarsoprol
Stage and subspecies dictate choice
▶
CSF staging mandatory for older regimens
Fexinidazole simplifies treatment
Resistance considerations
▶
Cross-resistance nifurtimox and fexinidazole
Directly observed therapy improves cure
Evidence base
▶
Fexinidazole pivotal trial
▶
Non-inferiority for late-stage gambiense
Oral therapy replacing IV regimens
WHO guideline evolution
▶
2019 to 2020 gambiense guidance
2024 rhodesiense expanded fexinidazole indications
Patient Discharge Instructions
copy discharge instructions
Copy
African sleeping sickness care plan
▶
Take all medication exactly as prescribed until finished
Take fexinidazole with a full meal every day
Keep every follow-up appointment, even if you feel well
Relapse can occur up to 12 to 24 months after treatment
Warning signs to return to the ER
▶
Return of fever, headache, or sleep problems
New confusion, tremor, unsteady walking, or seizures
Mood changes, hallucinations, or thoughts of self-harm
Chest pain, shortness of breath, or swelling
Severe vomiting or inability to keep fluids down
Follow-up schedule
▶
Clinic review at the times your specialist sets
Repeat testing to confirm cure
Bring this record to every visit
Prevention for future travel
▶
Wear long sleeves and neutral-colored clothing
Use insect repellent in endemic areas
Avoid bushland during peak tsetse biting hours
References
Guidelines and key sources
Guideline sources
▶
WHO guidelines for treatment of human African trypanosomiasis
WHO 2024 update on rhodesiense HAT and fexinidazole
CDC parasitic diseases guidance on African trypanosomiasis
Landmark evidence
▶
Mesu et al, pivotal fexinidazole trial for late-stage gambiense HAT, Lancet 2018
Lejon, Lindner, Franco, Human African Trypanosomiasis review, Lancet 2025
Betu Kumeso et al, acoziborole phase 2/3 trial, Lancet Infectious Diseases 2023
Coding standards
▶
ICD-10 B56.0 gambiense trypanosomiasis
ICD-10 B56.1 rhodesiense trypanosomiasis
ICD-10 B56.9 African trypanosomiasis unspecified
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.
← Management Protocols
Home
Management Protocols
African Sleeping Sickness